港股异动 | 医药股多数走强 国家医保局明确药品集采“反内卷”机构称板块估值仍具有吸引力

智通财经网
24 Jul

智通财经APP获悉,医药股多数走强,截至发稿,康希诺生物(06185)涨7.89%,报42.4港元;云顶新耀(01952)涨7.43%,报75.95港元;药明合联(02268)涨7.08%,报57.45港元;基石药业-B(02616)涨6.79%,报7.39港元;康方生物(09926)涨6.21%,报152.3港元。

消息面上,在今日举行的国新办新闻发布会上,国家医疗保障局副局长施子海在回应记者提问时表示,近期第十一批集采工作已经启动,国家医保局研究优化具体规则,在中选规则方面,优化价差的计算“锚点”,不再简单的以最低报价作为参考,同时,对于报价最低的中选企业,要公开说明报价的合理性,并承诺不低于成本报价。

中信建投证券表示,看好具有严格质量体系、具有规模成本优势、获得临床认可和广泛使用的产品在集采中维持甚至扩大市场份额。光大证券指出,港股医药板块估值收缩已持续数年,部分优质企业PE估值在反弹后仍具吸引力。考虑到部分创新药公司BD交易持续催化、细分赛道及正处于转型阶段的公司或有积极变化,该行认为应当积极关注板块高质量标的、增加板块配置。

更多港股重磅资讯,下载智通财经app

更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10